2025
Effect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis
Shah T, Zhang Z, Shah H, Fanaroff A, Nathan A, Parise H, Lutz J, Sugeng L, Bellumkonda L, Redfors B, Omerovic E, Petrie M, Vora A, Fiorilli P, Kobayashi T, Ahmad Y, Forrest J, Giri J, Herrmann H, Lansky A. Effect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis. JACC Cardiovascular Interventions 2025 PMID: 39985508, DOI: 10.1016/j.jcin.2024.11.036.Peer-Reviewed Original ResearchSodium-glucose cotransporter-2 inhibitorsCotransporter-2 inhibitorsAortic stenosisEffects of sodium-glucose cotransporter-2 inhibitorsProgression of aortic stenosisBaseline AS severityAssociated with slower progressionEchocardiographic follow-upRetrospective electronic medical record dataAortic valve sclerosisDisease-related morbidityChronic kidney diseaseSGLT2i usageRates of diabetesSevere ASAS severityEjection fractionFollow-upPrimary outcomeGt;1 yearKidney diseaseMedical record dataYale New Haven Health SystemPatientsObservational study
2022
Early Surgery for Patients With Asymptomatic Severe Aortic Stenosis: A Meta-Analysis of Randomized Controlled Trials
Ahmad Y, Howard J, Seligman H, Arnold A, Madhavan M, Forrest J, Geirsson A, Mack M, Lansky A, Leon M. Early Surgery for Patients With Asymptomatic Severe Aortic Stenosis: A Meta-Analysis of Randomized Controlled Trials. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 1: 100383. PMID: 39131941, PMCID: PMC11307849, DOI: 10.1016/j.jscai.2022.100383.Peer-Reviewed Original ResearchSurgical aortic valve replacementAsymptomatic severe aortic stenosisSevere aortic stenosisAortic stenosisHF hospitalizationCause mortalityEjection fractionPrespecified primary end pointSevere asymptomatic aortic stenosisSymptomatic severe aortic stenosisEnd pointAortic valve interventionAsymptomatic aortic stenosisHeart failure hospitalizationPrimary end pointAortic valve replacementClass I recommendationCornerstone of managementInitial conservative managementNormal ejection fractionRandomized Controlled TrialsCurrent treatment standardsIndividual end pointsAsymptomatic patientsEarly surgery